ライフサイエンスコーパス: gadolinium enhancement

1 mal ventricular function (4/5, 80% with late gadolinium enhancement).

2 and T2-weighted MR imaging before and after gadolinium enhancement.

3 mapping, rest first pass perfusion, and late gadolinium enhancement.

4 terisation with a suggestive pattern of late gadolinium enhancement.

5 ovascular obstruction was assessed with late gadolinium enhancement.

6 tures such as diastolic dysfunction and late gadolinium enhancement.

7 olic function, native T1 mapping, edema, and gadolinium enhancement.

8 jects in groups 3 and 4 had evidence of late gadolinium enhancement.

9 istribution is not well visualized with late gadolinium enhancement.

10 ncement and edema exceeding the area of late gadolinium enhancement.

11 Multivariable analysis adjusted for late gadolinium enhancement.

12 y LIBS-MPIOs and myocardial necrosis by late gadolinium enhancement.

13 s, 114 had a visible myocardial scar by late gadolinium enhancement.

14 showed intramyocardial and pericardial late gadolinium enhancement.

15 en death risk factors and 50 (37%) with late gadolinium enhancement.

16 No subjects had late gadolinium enhancement.

17 of myocardial perfusion, function, and late gadolinium enhancement.

18 Viability was assessed using late gadolinium enhancement.

19 0.37-0.47) but not with the presence of late gadolinium enhancement.

20 epared steady-state-free precession, or late gadolinium enhancement.

21 was identified by a diffuse pattern of late gadolinium enhancement.

22 ted after adjusting for the presence of late gadolinium enhancement.

23 line and 12 months, inclusive of T2 and late gadolinium enhancement.

24 e reported in 2 females with low T1 and late gadolinium enhancement.

25 T2, extracellular volume fraction, and late gadolinium enhancement.

26 y more specific than LVEF >35% with any late gadolinium enhancement.

27 xed ECV (iECV) to body surface area and late gadolinium enhancement.

28 f 6-month wall thickening compared with late gadolinium enhancement.

29 77.8% (14/18) of patients had focal late gadolinium enhancement.

30 nted with cerebral demyelinating lesions and gadolinium enhancement.

31 acterization of replacement fibrosis by late gadolinium enhancement.

32 h those of other cardiac MR parameters (late gadolinium enhancement, 0.90; T2 ratio, 0.79; extracellu

33 ortion of total left ventricular mass (%late gadolinium enhancement; 10.4+/-13.2% versus 8.5+/-8.5%;

34 elating with the presence or absence of late gadolinium enhancement (1001+/-82 versus 891+/-38 millis

35 1.8%) than those with both ischemia and late gadolinium enhancement (12.0%; P<0.001).

36 ger than the infarct size quantified by late gadolinium enhancement (37.2+/-11.6% versus 22.3+/-11.7%

37 ts without and in patients with evident late gadolinium enhancement (466 msec +/- 14, 406 msec +/- 59

38 of patients underwent cardiac MRI with late gadolinium enhancement 6 to 9 days after the index ST-se

39 The presence of late gadolinium enhancement (65% versus 64%; P=0.99) and the

40 jection fraction (73% versus 68%), more late gadolinium enhancement (85% versus 15%), and a lower str

41 SP and were strongly associated with LV late gadolinium enhancement (90%), even in cases of acute myo

42 structural and functional adaptations (late gadolinium enhancement/abnormal innervation) with detail

43 uptake, as well as transmural extent of late gadolinium enhancement, acutely can identify viable myoc

44 rization, electric markers of scar, and late gadolinium enhancement (all P<0.001).

45 ts with myocardial scar determined with late gadolinium enhancement and 286 age-, sex-, and ethnicity

46 ascular magnetic resonance imaging with late gadolinium enhancement and a 24-hour Holter.

47 ic resonance showed regional transmural late gadolinium enhancement and edema exceeding the area of l

48 Both transmural extent of late gadolinium enhancement and FDG uptake on the acute scan

49 sed with ALVC, defined as a LV isolated late gadolinium enhancement and fibro-fatty replacement at ca

50 s regarding the presence of abnormal orbital gadolinium enhancement and judged them as "definitive tu

51 Across all FD, late gadolinium enhancement and low native T1 were independen

52 magnetic resonance protocol, including late gadolinium enhancement and mapping sequences in sarcoid

53 g was performed as well as early and delayed gadolinium enhancement and systolic function assessment.

54 this zone was most commonly spared from late gadolinium enhancement and T2 abnormalities, typically s

55 All animals underwent MRI (late gadolinium enhancement and T2-weighted edema imaging) im

56 T1, T2, global longitudinal strain, and late gadolinium enhancement) and biomarkers (high-sensitive t

57 was performed to quantify regional (by late-gadolinium enhancement) and diffuse (by T1 mapping) myoc

58 ate gadolinium enhancement (ventricular late gadolinium enhancement) and diffuse fibrosis with postco

59 CMR DENSE, late gadolinium enhancement, and electrical timing together c

60 presence of a CMR diagnosis, extent of late gadolinium enhancement, and left and right ventricular e

61 ne stress/rest perfusion, cine imaging, late gadolinium enhancement, and magnetic resonance coronary

62 and function, infarct size assessed by late gadolinium enhancement, and myocardial strain.

63 , strain imaging by myocardial tagging, late gadolinium enhancement, and native T1 mapping (Shortened

64 erformed to assess cardiac function and late gadolinium enhancement, and T1 and T2 mapping.

65 al associations among stress perfusion, late gadolinium enhancement, and T2 imaging were made at segm

66 rformed, followed by CMR (cine imaging, late gadolinium enhancement, and T2-weighted imaging and T1 m

67 Cine, stress perfusion, late gadolinium enhancement, and T2-weighted imaging techniqu

68 ocardial velocities, scar determined by late gadolinium enhancement, and wall motion abnormalities.

69 ed disease controls increased T2 in the late gadolinium enhancement area (57+/-6 versus 60+/-7 ms; P=

70 gher troponin T peak (P<0.0001), larger late gadolinium enhancement area (P<0.0001), and lower left v

71 r troponin T peak (P=0.006) but similar late gadolinium enhancement area (P=0.24) compared with those

72 and focal fibrosis (59% had nonischemic late gadolinium enhancement, as compared with 14% in HTN subj

73 ons of HCM subjects without evidence of late gadolinium enhancement, as well as of hypertensive patie

74 c magnetic resonance imaging, including late gadolinium enhancement assessment of fibrosis.

75 Transverse pancakelike gadolinium enhancement associated with and just caudal t

76 ing the first trimester of pregnancy or with gadolinium enhancement at any time of pregnancy is unkno

77 A total of 72 patients (72%) showed late gadolinium enhancement at baseline with 57 (57%) having

78 tive/postcontrast T1 maps, T2 maps, and late gadolinium enhancement at days 1 and 21 post-MI.

79 The presence of late gadolinium enhancement at magnetic resonance imaging, a

80 The presence of late gadolinium enhancement at magnetic resonance imaging, a

81 There was no change in volume of late gadolinium enhancement at treatment.

82 ognostic value of inducible ischemia or late gadolinium enhancement by CMR.

83 ngs of left ventricular hypertrophy and late gadolinium enhancement can be used to identify patients

84 The association of scar on late gadolinium enhancement cardiac magnetic resonance (LGE-C

85 Scar signal quantification using late gadolinium enhancement cardiac magnetic resonance (LGE-C

86 ostic value of the peri-infarct zone on late gadolinium enhancement cardiac magnetic resonance in isc

87 electrophysiology mapping) and advanced late gadolinium enhancement cardiac magnetic resonance scar i

88 opathy and drug-refractory VT underwent late gadolinium enhancement cardiac MRI (CMR), (123)I-metaiod

89 uscular dystrophy, myocardial damage by late gadolinium enhancement cardiac MRI and preserved ejectio

90 Late-gadolinium-enhancement cardiac MRI (LGE-MRI) assessment

91 hteen consecutive patients referred for late gadolinium enhancement-cardiac magnetic resonance and a

92 Future studies should confirm whether late gadolinium enhancement-cardiac magnetic resonance assess

93 Late gadolinium enhancement-cardiac magnetic resonance is inc

94 patients underwent clinical evaluation, late gadolinium enhancement cardiovascular magnetic resonance

95 d by midwall hyperenhancement (MWHE) on late gadolinium enhancement cardiovascular magnetic resonance

96 ipients, myocardial fibrosis is seen on late gadolinium enhancement cardiovascular magnetic resonance

97 etermine whether myocardial fibrosis on late gadolinium enhancement cardiovascular magnetic resonance

98 Midwall fibrosis is identified by late gadolinium enhancement cardiovascular magnetic resonance

99 Cine and late gadolinium enhancement cardiovascular MR and 2-dimension

100 Late gadolinium enhancement-cardiovascular magnetic resonance

101 Conversely, late gadolinium enhancement CMR should be postponed in the te

102 sine stress 3D myocardial perfusion and late gadolinium enhancement CMR.

103 UMI was defined as the presence of late gadolinium enhancement consistent with MI in the absence

104 The edema volume in late gadolinium enhancement correlated well with edema volume

105 Heterogeneous gadolinium enhancement, cortical thickness, round shape,

106 Infarct size (late gadolinium enhancement) decreased after CSC infusion (by

107 Indexed MRI-late gadolinium enhancement-defined infarct size was 18.3 (IQ

108 In individuals without a late gadolinium enhancement-defined myocardial scar (n = 1131

109 CMR-LVEF </=35% or CMR-LVEF </=35% plus late gadolinium enhancement detection showed a higher perform

110 5.2% ( P=0.0001) with prevalence of any late gadolinium enhancement dropping to 48%.

111 l perfusion, microvascular obstruction, late gadolinium enhancement, edema, and intramyocardial hemor

112 Patients without ischemia or late gadolinium enhancement experienced a lower annual event

113 Dorsal cord subpial gadolinium enhancement extending >/=2 vertebral segments

114 nstrated that (18)F-FDG extent exceeded late gadolinium enhancement extent (33.2+/-16.2% left ventric

115 Global late gadolinium enhancement extent dropped from 8.5+/-9.2% of

116 Extracellular volume for diffuse and late gadolinium enhancement for focal fibrosis were assessed.

117 Late gadolinium enhancement for replacement fibrosis was dete

118 98% completed stress CMR, 82% completed late gadolinium enhancement for viability, 94% completed live

119 permanent pacemaker and LVEF >35% with late gadolinium enhancement >5.7%, had high annualized event

120 higher baseline hs-cTnT categories and late gadolinium enhancement (>/=7.42 ng/L versus <limit of de

121 tio=2.18 [1.3-3.8]) and the presence of late gadolinium enhancement (hazard ratio=2.2 [1.4-3.6]) were

122 Late gadolinium enhancement, however, relies on the regional

123 In parallel, late gadolinium enhancement identified the extent of myocardi

124 crovascular obstruction region on acute late gadolinium enhancement images acquired 26.1 minutes afte

125 Late gadolinium enhancement images were acquired to detect my

126 Late gadolinium enhancement images were blindly interpreted f

127 enosis was removed, and T2-weighted and late-gadolinium-enhancement images were acquired.

128 um were identified from postreperfusion late-gadolinium-enhancement images.

129 s underwent CMR including cine imaging, late gadolinium enhancement imaging (LGE) (replacement fibros

130 Late gadolinium enhancement imaging is an established method

131 Late gadolinium enhancement imaging was abnormal in 79 patien

132 Quantification of fibrosis from late gadolinium enhancement imaging was incrementally perform

133 or first pass myocardial perfusion, and late gadolinium enhancement imaging), transthoracic echocardi

134 of cine, rest first-pass perfusion, and late gadolinium enhancement imaging.

135 etic resonance imaging was positive for late gadolinium enhancement in 21 of 23 (91%) patients, where

136 haracteristic pancakelike transverse band of gadolinium enhancement in 41 (73%), typically immediatel

137 Preoperative CMR showed late gadolinium enhancement in 70% of the patients, whereas E

138 One subject in group 2 had late gadolinium enhancement in a noncoronary distribution, an

139 normal LV contractility and absence of late gadolinium enhancement in all but one patient.

140 There was no late gadolinium enhancement in any of the participants before

141 le for electrocardiographic imaging and late gadolinium enhancement in early diagnosis and noninvasiv

142 increase in the frequency of noninfarct late gadolinium enhancement in PA (70%) when compared with es

143 cardiac magnetic resonance imaging with late gadolinium enhancement in phenotyping the left ventricul

144 CMR at 1.5 T including cine, DENSE, and late gadolinium enhancement in subjects >45 years.

145 erwent CMR at 3.0 T including cine, and late gadolinium enhancement in subjects >45 years.

146 Cardiac magnetic resonance showed LV late gadolinium enhancement in the LV lateral and posterior b

147 in early disease stages and complements late gadolinium enhancement in visualization of the regional

148 rted for any mice, and the first use of late-gadolinium-enhancement in a mouse model of congenital ca

149 al injury could improve the accuracy of late gadolinium-enhancement in predicting functional recovery

150 Gadolinium enhancement indicates blood-brain barrier (BB

151 etic resonance (CMR) to assess LVEF and late gadolinium enhancement, indicative of ventricular fibros

152 sion wave was inversely correlated with late-gadolinium enhancement infarct mass (r=-0.81; P<0.0001)

153 a CMR diagnosis and some CMR parameters-late gadolinium enhancement, left ventricular ejection fracti

154 rier compromise was suggested by parenchymal gadolinium enhancement, leukocyte recruitment, and endot

155 Cardiac magnetic resonance late gadolinium enhancement (LGE) and feature-tracking are ca

156 Patients with late gadolinium enhancement (LGE) and low lateral MAPSE had s

157 the association between local CV versus late gadolinium enhancement (LGE) and myocardial wall thickne

158 Cardiac magnetic resonance (CMR), with late gadolinium enhancement (LGE) and T1 mapping, is emerging

159 ameters at diagnosis predict dynamic of late gadolinium enhancement (LGE) as persistent LGE has been

160 nction and tissue characterization with late gadolinium enhancement (LGE) as well as T1 and T2 mappin

161 ere are scarce data on the influence of late gadolinium enhancement (LGE) assessed by cardiovascular

162 t ventricular quantitative analysis and late gadolinium enhancement (LGE) assessments and analyzed th

163 ce of ventricular fatty replacement and late gadolinium enhancement (LGE) at cardiac magnetic resonan

164 Late gadolinium enhancement (LGE) border zone on cardiac magn

165 t studies have evaluated the ability of late gadolinium enhancement (LGE) by cardiac magnetic resonan

166 Prior studies have shown that late gadolinium enhancement (LGE) by cardiac magnetic resonan

167 Late gadolinium enhancement (LGE) by cardiac MR (CMR) is a pr

168 Patients with no ischemia or late gadolinium enhancement (LGE) by CMR, observed in 1,583 p

169 eported an inverse relationship between late gadolinium enhancement (LGE) cardiac magnetic resonance

170 Late gadolinium enhancement (LGE) cardiac magnetic resonance

171 We investigated whether late gadolinium enhancement (LGE) cardiovascular magnetic res

172 hypothesized that fibrosis detected by late gadolinium enhancement (LGE) cardiovascular magnetic res

173 r VT, can be noninvasively defined with late gadolinium enhancement (LGE) cardiovascular magnetic res

174 Late gadolinium enhancement (LGE) cardiovascular magnetic res

175 Late gadolinium enhancement (LGE) cardiovascular magnetic res

176 h cardiovascular magnetic resonance for late gadolinium enhancement (LGE) detection and quantificatio

177 levation myocardial infarction (STEMI), late gadolinium enhancement (LGE) has been demonstrated to ov

178 cardiovascular magnetic resonance with late gadolinium enhancement (LGE) has emerged as an in vivo m

179 of cardiac magnetic resonance (CMR) and late gadolinium enhancement (LGE) has not been clarified in a

180 have demonstrated regional left atrial late gadolinium enhancement (LGE) heterogeneity on magnetic r

181 e inversion-recovery (STIR) images, and late gadolinium enhancement (LGE) images were acquired.

182 Late gadolinium enhancement (LGE) imaging overestimates acute

183 D by assessing myocardial perfusion and late gadolinium enhancement (LGE) imaging.

184 extracellular volume fraction (ECV) and late gadolinium enhancement (LGE) in children and young adult

185 Areas of late gadolinium enhancement (LGE) in each image were assigned

186 c significance of left ventricular (LV) late gadolinium enhancement (LGE) in patients with atrial fib

187 Cardiovascular magnetic resonance with late gadolinium enhancement (LGE) is a reference standard for

188 Late gadolinium enhancement (LGE) is an important prognostic

189 art of a CMR protocol including MPI and late gadolinium enhancement (LGE) is not well established.

190 cardiovascular magnetic resonance with late gadolinium enhancement (LGE) is unresolved.

191 Myocardial fibrosis was detected by late gadolinium enhancement (LGE) MRI, and myocardial perfusi

192 s that magnetic resonance imaging (MRI) late gadolinium enhancement (LGE) of the coronary vessel wall

193 isolated LV subepicardial/midmyocardial late gadolinium enhancement (LGE) on contrast-enhanced cardia

194 ted myocarditis underwent CMR including late gadolinium enhancement (LGE) parameters between 2002 and

195 Currently, late gadolinium enhancement (LGE) scans provide the only noni

196 Background Cardiac MRI late gadolinium enhancement (LGE) scar volume is an important

197 d that achieved by the well-established late gadolinium enhancement (LGE) technique (which detects fo

198 Left ventricular hypertrophy (LVH) and late gadolinium enhancement (LGE) were independent predictors

199 on the association of left atrial (LA) late gadolinium enhancement (LGE) with atrial voltage in pati

200 The presence of late gadolinium enhancement (LGE) yields a hazard ratio of 8.

201 dial damage, defined by the presence of late gadolinium enhancement (LGE), (2) quantify their risk of

202 rt-axis slice of native T1 map, T2 map, late gadolinium enhancement (LGE), and automated extracellula

203 le) underwent DT-CMR in diastole, cine, late gadolinium enhancement (LGE), and extracellular volume (

204 ntal wall thickening percent, segmental late Gadolinium enhancement (LGE), and extracellular volume f

205 rest, hyperemia perfusion defect (PD), late gadolinium enhancement (LGE), and inducible WMA were ana

206 o detecting myocardial fibrosis through late gadolinium enhancement (LGE), extracellular volume fract

207 (HCM) myocardial fibrosis, detected by late gadolinium enhancement (LGE), is associated to a progres

208 of reactive interstitial fibrosis, and late gadolinium enhancement (LGE), representing replacement f

209 of 1,228 patients with AF who underwent late gadolinium enhancement (LGE)-cardiac magnetic resonance

210 is of the myocardium is detectable with late gadolinium enhancement (LGE).

211 hy, and cardiac magnetic resonance with late gadolinium enhancement (LGE); all 3 tests were <24 hours

212 ow native T1 (sphingolipid storage) and late gadolinium enhancement (LGE, scar).

213 ge transmural (volume of enhancement on late gadolinium enhancement [LGE] images >20%, n = 72) or sma

214 arated imaging, focal fibrosis imaging (late gadolinium enhancement [LGE]), and (1)H magnetic resonan

215 ft ventricular function, and myocardial late gadolinium enhancement [LGE]), and metabolic parameters

216 elaxation times, ECV, myocardial edema, late gadolinium enhancement [LGE], and myocardial strain) par

217 rs) underwent T2-weighted, tagging, and late gadolinium enhancement magnetic resonance imaging at thr

218 icrovascular resistance correlated with late-gadolinium enhancement mass (r=0.48; P=0.03) but not lef

219 with LFLG-AS have higher ECV, iECV, and late gadolinium enhancement mass compared with high-gradient

220 Late gadolinium enhancement mass was also similar in patients

221 cular ejection fraction, and percentage late-gadolinium enhancement mass were 1.35+/-1.21 microg/L, 5

222 e-breathing, motion-corrected, averaged late-gadolinium-enhancement (moco-LGE) cardiovascular MR may

223 dance, and gap lengths determined using late gadolinium enhancement MR images were correlated with ga

224 T2-weighted, native T1/T2 mapping, and late gadolinium enhancement MR imaging.

225 We hypothesized that late gadolinium enhancement MRI (LGE-MRI) can identify left a

226 tip placement through coregistration of late gadolinium enhancement MRI and cardiac computed tomograp

227 erize different areas of enhancement in late gadolinium enhancement MRI done immediately after ablati

228 -tesla MRI system where high-resolution late gadolinium enhancement MRI was used to identify the gap.

229 ents receiving CRT underwent preimplant late gadolinium enhancement MRI, postimplant cardiac CT, and

230 gaps up to 1.4 mm were identified using late gadolinium enhancement MRI.

231 with clinical cardiovascular disease or late gadolinium enhancement (n = 167), and after replacing LV

232 o), early gadolinium enhancement ratio, late gadolinium enhancement, native T1 relaxation times, and

233 Most of these patients were late gadolinium enhancement negative.

234 asured in 27 subjects, all of whom were late gadolinium enhancement negative.

235 rea of gadolinium enhancement (t(1)) and two gadolinium enhancement-negative follow-up evaluations af

236 ted by rest and stress perfusion imaging and gadolinium enhancement obtained 2 min.

237 LV late gadolinium enhancement occurred with normal LV systolic

238 At baseline, a lower extent of late gadolinium enhancement (odds ratio [OR]: 0.67 [95% confi

239 iRNAs were also decreased in patients with a gadolinium enhancement on brain magnetic resonance imagi

240 years) arrhythmic MVP patients with LV late gadolinium enhancement on cardiac magnetic resonance and

241 at baseline evaluation, the presence of late gadolinium enhancement on cardiac magnetic resonance ima

242 fraction was 51% (+/-17%), and 32% had late gadolinium enhancement on cardiac magnetic resonance.

243 Nineteen percent had late gadolinium enhancement on cardiac magnetic resonance.

244 jection fraction (LVEF) >35% with >5.7% late gadolinium enhancement on cardiovascular magnetic resona

245 Only 1 patient presented with late gadolinium enhancement on cardiovascular magnetic resona

246 letes but none of the controls revealed late gadolinium enhancement on cardiovascular magnetic resona

247 ere required to have early-stage disease and gadolinium enhancement on magnetic resonance imaging (MR

248 atecholamine levels, RV dilatation, and late gadolinium enhancement on MRI, increased (18)fluorodeoxy

249 Diabetics without late gadolinium enhancement or inducible ischemia had a low a

250 associated with increased occurrence of late gadolinium enhancement (P=0.004).

251 as mainly asymmetrical, and had similar late gadolinium enhancement patterns.

252 with both imaging modalities and higher late gadolinium enhancement per-patient prevalence as compare

253 Gadolinium enhancement persisted in 75% at 12 months, ra

254 ll patients with ECG strain had midwall late gadolinium enhancement (positive and negative predictive

255 In those undergoing CA, the absence of late gadolinium enhancement predicted greater improvements in

256 The optimal cutoff for the extent of late gadolinium enhancement predictive of the composite end p

257 and fibro-fatty replacement in areas of late gadolinium enhancement presence.

258 agnetic resonance evidence of regional (late-gadolinium enhancement quantity, 6.4+/-8.0%) and diffuse

259 nd closely correlated with the areas of late gadolinium enhancement (R 0.98) with a small bias of 2.0

260 ; extracellular volume fraction, 0.71; early gadolinium enhancement ratio, 0.63; P = .390, .018, .002

261 , 1.6+/-0.3 versus 1.4+/-0.3; P=0.046; early gadolinium enhancement ratio, 3.1+/-1.2 versus 2.1+/-0.6

262 was superior to that with T2 ratio and early gadolinium enhancement ratio, and specificity was higher

263 ery signal intensity ratio (T2 ratio), early gadolinium enhancement ratio, late gadolinium enhancemen

264 Myocardial fibrosis was determined with late gadolinium enhancement (replacement fibrosis) and T1 map

265 1.8 mV; 3 abnormal SAECG parameters; delayed gadolinium enhancement, RV ejection fraction </=45%, or

266 ological abnormalities colocalized with late gadolinium enhancement scar, indicating a relationship w

267 rential strain (Ecc), segmental area of late gadolinium-enhancement (SEE), microvascular obstruction,

268 ntal comparison of (18)F-FDG-uptake and late gadolinium enhancement showed substantial overlap (kappa

269 fter excluding myocardial segments with late gadolinium enhancement, significant relationships betwee

270 Indexed late gadolinium enhancement significantly decreased in G-CSF

271 native T1 mapping, with no evidence of late gadolinium enhancement suggestive of replacement fibrosi

272 brain scan positive for at least one area of gadolinium enhancement (t(1)) and two gadolinium enhance

273 0.016) were higher in MVP patients with late gadolinium enhancement than in those without.

274 tifying focal ventricular fibrosis with late gadolinium enhancement (ventricular late gadolinium enha

275 cose score was highest in segments with late gadolinium enhancement versus edema only and remote (med

276 was in good agreement with the 6-month late gadolinium enhancement volume (r=0.99) and correlated st

277 In addition, late gadolinium enhancement was also assessed.

278 The presence of late gadolinium enhancement was also significantly associated

279 Late gadolinium enhancement was assessed by using gradient-ec

280 Late gadolinium enhancement was assessed with CMR.

281 l LS and CS 2DST and 2DTagg to identify late gadolinium enhancement was compared using receiver opera

282 Myocardial fibrosis by late gadolinium enhancement was detected in 15.8% of the pati

283 1) spondylotic myelopathy was suspected, (2) gadolinium enhancement was detected, and (3) spinal surg

284 Indeed, late gadolinium enhancement was independently associated with

285 ventricular ejection fraction was 65%; late gadolinium enhancement was only present in sarcoid patie

286 Late gadolinium enhancement was present in >60% of overt pati

287 r ejection fraction was 61 +/- 12%; and late gadolinium enhancement was present in 29% and ischemia i

288 LV late gadolinium enhancement was present in a primarily subepi

289 que rupture was found in nearly 40% and late gadolinium enhancement was seen in nearly 40%, with litt

290 farcted versus noninfarcted segments by late gadolinium enhancement was similarly good for regional L

291 er injection and imaging of LIBS-MPIOs, late gadolinium enhancement was used to depict myocardial nec

292 Regional left ventricular function and late-gadolinium enhancement were assessed by cardiac magnetic

293 entricular dilation and the presence of late gadolinium enhancement were inversely correlated to hepa

294 age: 40 years) MVP patients without LV late gadolinium enhancement were investigated by morphofuncti

295 Both ECV and late gadolinium enhancement were more extensive in sarcomeric

296 -Meier analysis, inducible ischemia and late gadolinium enhancement were significantly associated wit

297 el, PET tracer uptake, wall motion, and late gadolinium enhancement were visually assessed for each s

298 patients with SCD (25%) had evidence of late gadolinium enhancement, whereas only 1 patient had evide

299 egional diffuse fibrosis not visible by late gadolinium enhancement, which was associated with impair

300 e represents sphingolipid accumulation; late gadolinium enhancement with high T2 and troponin elevati